21 hours ago tipranks hims and hers health call volume above normal and directionally bullish april 24, 2025 tipranks fda alert on finasteride could elevate churn for hims & hers, says bofa april 23, 2025 tipranks hims & hers stock (hims) dips after fda flags safety concerns ...
用富途牛牛查看Hims & Hers Health(HIMS)的股票价格、即时报价、最新新闻、历史走势图、财务信息和行情。
Check the Hims & Hers Health, Inc. stock price today on the NYSE stock exchange and access historical HIMS stock price chart. Get the latest Hims & Hers Health, Inc. stock information.
Hims & Hers vs. Teladoc: Which Telehealth Stock Is the Better Buy Now? 5 hours ago•Zacks Markets HIMS Factor-Based Stock Analysis 7 hours ago•Validea Stocks Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical records system, digital prescriptions and cloud-enabled pharmacy fulfillment. Its ...
Hims & Hers Health, Inc.’sHIMSinvestors have been experiencing some short-term gains from the stock of late. Shares of the San Francisco, CA-based health and wellness platform have surged 156.9% in the past three months, outperforming theindustry’s 28.3% gain. In the same time frame, the...
Use Futu NiuNiu to view Hims & Hers Health (HIMS)'s stock price, real-time quotes, latest news, historical trend charts, financial information and quotes.
Information on stock, financials, earnings, subsidiaries, investors, and executives for Hims & Hers Health. Use the PitchBook Platform to explore the full profile.
1-year stock price forecast HIMS Competitors $ Market capP/E ratio$ Price1d change52-week range HIMS Hims & Hers Health, Inc. Class A 9.13B 76.70x 40.82 12.89% 11.2072.98 EHC Encompass Health Corporation 11.76B 24.10x 116.64 0.60%
Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in Eli Lilly’s Wegovy and Novo Nordisk’s Ozempic has been resolved.